Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Glomerular Filtration Rate, its Association with Risk Factors and Cardiovascular Diseases. The Results of the ESSE-RF-2 Study

https://doi.org/10.20996/1819-6446-2020-04-09

Full Text:

Abstract

Aim. To study the influence of social determinants on the frequency of glomerular filtration rate (GFR) categories of various levels, as well as associations with a number of cardiovascular diseases (CVD) and cardiovascular risk factors among the population of four Russian regions included in the ESSE-RF-2.

Material and methods. The study was performed as part of a multicenter epidemiological study “Epidemiology of cardiovascular diseases in the regions of the Russian Federation. The second study (ESSE-RF-2)”. In total, 6681 people 25-64 years old from 4 regions of Russian Federation were included in the analysis. The CKD-EPI formula was used to calculate GFR by blood creatinine level. Groups with normal GFR (≥90 ml/min/1.73 m²), with an initial decrease in GFR (<90 ml/min/1.73 m²), and with a decrease in GFR (<60 ml/min/1.73 m²) were distinguished for statistical analysis. Generalized linear/nonlinear analysis (GLM) was used for multivariate assessment and adjustment of results to socio-demographic characteristics.

Results. The average GFR level in the total sample was 97.8±16.6 ml/min/1.73 m2 ; 29.0% of individuals had an initial decrease in GFR, 1.6% had a reduced GFR. Age was significantly associated with GFR. A statistically significant association with an initial decrease in GFR was found for: hypercholesterolemia (odds ratio [OR] 1.22; 95% clearance interval [95%CI] 1.14-1.30), hypertriglyceridemia (OR 1.09; 95%CI 1.02-1.17), hyperuricemia (OR 1.51; 95%CI 1.39-1.63), no smoking (OR 0.79; 95%CI 0.73-0.85), history of kidney disease (OR 1.13; 95%CI 1.04-1.22). A more pronounced decrease in GFR was associated with the following factors and diseases: arterial hypertension (OR 1.48; 95%CI 1.07-2.05), low level of high-density lipoproteins (OR 1.36; 95%CI 1.04-1.79), hypertriglyceridemia (OR 1.37; 95%CI 1.08-1.76), hyperuricemia (OR 2.49; 95%CI 1.97-3.16), hyperglycemia (OR 1.35; 95%CI 1.01-1.80), a history of myocardial infarction (OR 1.63; 95%CI 1.13-2.36) and kidney disease (OR 1.50; 95%CI 1.16-1.93).

Conclusion. The results of the study indicate a greater number of factors and diseases associated with low GFR compared with the initial decrease, which emphasizes the need for early detection of signs of chronic kidney disease, especially in the elderly, in people with metabolic syndrome, hypertension or diabetes mellitus, as well as a history of kidney disease.

About the Authors

S. A. Shalnova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Svetlana A. Shalnova – MD, PhD, Professor, Head of Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



S. A. Maksimov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Sergey A. Maksimov – MD, PhD, Associate Professor, Leading Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



Yu. A. Balanova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Yulia A. Balanova – MD, PhD, Leading Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



S. E. Evstifeeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Svetlana E. Evstifeeva – MD, PhD, Senior Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



A. E. Imaeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Asiia E. Imaeva – MD, PhD, Senior Researcher, Department of Epidemiology of Chronic NonCommunicable Diseases

Petroverigsky per. 10, Moscow, 101990



A. V. Kapustina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Anna V. Kapustina – MD, Senior Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



G. A. Muromtseva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Galina A. Muromtseva – PhD (Biology), Leading Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



V. I. Tarasov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Vladimir I. Tarasov – PhD (Physics and Mathematics), Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990



I. A. Viktorova
Omsk State Medical University
Russian Federation

Inna A. Viktorova – MD, PhD, Professor, Head of Chair of Internal Medicine and Outpatient Therapy

Lenina ul. 12, Omsk, 644099



A. N. Redko
Kuban State Medical University
Russian Federation

Andrey N. Redko – MD, PhD, Professor, Head of Chair of Public Health, Health and Medical History

Mitrofana Sedina ul. 4, Krasnodar, 350063



N. N. Prishchepa
Center for Medical Prevention of the Republic of Karelia
Russian Federation

Natalia N. Prishchepa – MD, Head of Center for Medical Prevention of the Republic of Karelia

Kirov ul. 3, Petrozavodsk, 185000



S. S. Yakushin
Ryazan State Medical University named after Academician I.P. Pavlov
Russian Federation

Sergey S. Yakushin – MD, PhD, Professor, Head of Chair of Hospital Therapy

Visokovoltnaya ul. 9, Ryazan, 390026



O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Oxana M. Drapkina – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director

Petroverigsky per. 10, Moscow, 101990



References

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(S1):1-266. DOI:CliCa0405689692.

2. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease [cited by March 13, 2020]. Available from: www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf. DOI:10.1007/s11255-014-0761-7.

3. Coresh J. Update on the Burden of CKD. J Am Soc Nephrol. 2017;28(4):1020-2. DOI:10.1681/ASN.2016121374.

4. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-69. DOI:10.1161/01.CIR.0000095676.90936.80.

5. Maslova O.V., Suntsov Y.I., Shestakova M.V., et al. Prevalence of diabetic nephropathy in Russian Federation. Klinicheskaya Nefrologiya. 2010;(3):45-50 (In Russ.)

6. Moiseev V.S., Mukhin N.A., Smirnov A.V. et al. Cardiovascular risk and chronic kidney disease: cardionephroprotection strategies. Russian Journal of Cardiology 2014;(8):7-37 (In Russ.) DOI:10.15829/1560-4071-2014-8-7-37.

7. Wu J., Jia J., Li Z., et al. Association of estimated glomerular filtration rate and proteinuria with allcause mortality in community-based population in China: A Result from Kailuan Study. Sci Rep. 2018;8(1):2157. DOI:10.1038/s41598-018-20554-3.

8. Kramer H., Boucher R., Leehey D., et al. Increasing mortality in adults with diabetes and low estimated glomerular filtration rate in the absence of albuminuria. Diabetes Care. 2018;41:775-81. DOI:10.2337/dc17-1954.

9. Afkarian M., Sachs M.C., Kestenbaum B., et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-8. DOI:10.1681/ASN.2012070718.

10. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603-58. DOI:10.1016/S0140-6736(16)31460-X.

11. New Report Captures the High Burden, High Cost and Low Awareness of Kidney Disease in the United States. 2017 Annual Data Report Highlights. [cited by March 13, 2020]. Available from: https://www.usrds.org/2016/pres/The_State_of_Kidney_Disease_in_US.pdf.

12. Oshchepkova E.V., Dolgusheva I.A., Zhernakova I.V., et al. The prevalence of renal dysfunction in arterial hypertension (in the framework of the ESSE-RF study). Systemic Hypertension. 2015;12(3):19- 24 (In Russ.) DOI:10.26442/2075-082X_12.3.19-24.

13. Kobalava Z.D., Villevalde S.V., Bagmanova N.K., et al. Тhe prevalence of chronic kidney disease markers in arterial hypertension patients and relation with diabetes: results of epidemiological study KHRONOGRAPH. Russian Journal of Cardiology. 2018;(2):91-101 (In Russ.) DOI:10.15829/1560-4071-2018-2-91-101.

14. Nagaitseva S.S., Shvetsov M.Yu., Lukshina L.P., et al. Newly-diagnosed chronic kidney disease in patients of a therapeutic clinic: the role of gfr calculation by the CKD-EPI formula. Klinicheskaya Meditsina. 2015;93(7):56-61 (In Russ)

15. Boytsov S.A., Chazov E.I., Shlyakhto E.V., et al. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Profilakticheskaya Meditsina. 2013;16(6):25-34 (In Russ.)

16. Michels W.M., Grootendorst D.C., Verduijn M., et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003-1009. DOI:10.2215/CJN.06870909.

17. Shalnova S.A., Maksimov S.A., Balanova Y.A., et al. Alcohol consumption and dependence on sociodemographic factors in able-bodied people (according to the ESSE-RF study). Profilakticheskaya Meditsina. 2019;22(5):45-53 (In Russ.) DOI:10.17116/profmed20192205145.

18. Glassock R.J., Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419-28.

19. Wouters O.J., O'Donoghue D.J., Ritchie J., et al. Early chronic kidney disease: diagnosis, management and models of care. Nat Rev Nephrol. 2015;11(8):491-502. DOI:10.1038/nrneph.2015.85.

20. Ogna V.F., Ogna A., Ponte B., et al. Prevalence and determinants of chronic kidney disease in the Swiss population. Swiss Med Wkly. 2016;146:w14313. DOI:10.4414/smw.2016.14313.

21. O’Callaghan-Gordo C., Shivashankar R., Anand S., et al. Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies. BMJ Open. 2019;9:e023353. DOI:10.1136/bmjopen-2018-023353.

22. Sakurai M., Kobayashi J., Takeda Y., et al. Sex differences in associations among obesity, metabolic abnormalities, and chronic kidney disease in japanese men and women. Epidemiol. 2016;26(8):440-446 DOI:10.2188/jea.JE20150208.

23. Orth S.R., Hallan S.I. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients – absence of evidence or evidence of absence? Clin J Am Soc Nephrol. 2008;3:226-36. DOI:10.2215/CJN.03740907.

24. Vupputuri S., Sandler D.P. Lifestyle risk factors and chronic kidney disease. Ann Epidemiol. 2003;13(10):712-20. DOI:10.1016/s1047-2797(03)00066-8.

25. Verhave J.C., Hillege H.L., Burgerhof J.G., et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int. 2005;67(5):1967-73. DOI:10.1111/j.1523-1755.2005.00296.x.


For citation:


Shalnova S.A., Maksimov S.A., Balanova Y.A., Evstifeeva S.E., Imaeva A.E., Kapustina A.V., Muromtseva G.A., Tarasov V.I., Viktorova I.A., Redko A.N., Prishchepa N.N., Yakushin S.S., Drapkina O.M. Glomerular Filtration Rate, its Association with Risk Factors and Cardiovascular Diseases. The Results of the ESSE-RF-2 Study. Rational Pharmacotherapy in Cardiology. 2020;16(2):240-249. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-09

Views: 131


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)